Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
697 Burke Road
Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
stocks
Cisco earnings: AI orders and profitability look strong despite second-half choppiness
We’ve raised our fair value estimate of Cisco stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.20 | 16.20 | -0.18% |
| CAC 40 | 8,340.56 | 27.32 | 0.33% |
| DAX 40 | 24,852.69 | 3.46 | -0.01% |
| Dow JONES (US) | 49,694.37 | 427.03 | -0.85% |
| FTSE 100 | 10,402.44 | 69.67 | -0.67% |
| HKSE | 27,032.54 | 233.84 | -0.86% |
| NASDAQ | 22,726.81 | 339.66 | -1.47% |
| Nikkei 225 | 57,639.84 | 10.70 | -0.02% |
| NZX 50 Index | 13,427.44 | 79.84 | -0.59% |
| S&P 500 | 6,872.16 | 69.31 | -1.00% |
| S&P/ASX 200 | 8,965.50 | 7.40 | -0.08% |
| SSE Composite Index | 4,134.02 | 2.03 | 0.05% |